1.Clinical cure strategies for chronic hepatitis B patients with hepatitis B virus surface antigen <100 IU/mL after treatment with nucleos(t)ide analogues
Junfeng LU ; Shan REN ; Sujun ZHENG ; Xinyue CHEN
Journal of Clinical Hepatology 2026;42(4):777-781
Among chronic hepatitis B patients undergoing long-term treatment with nucleos(t)ide analogues (NAs), approximately 10%—20% can achieve a low level of <100 IU/mL for hepatitis B surface antigen (HBsAg). These patients have the advantage to achieve clinical cure (HBsAg clearance) and are currently a key focus for treatment discontinuation and combination treatment strategies. As for the selection of clinical management strategies, the NAs discontinuation strategy, based on the “immune reactivation” hypothesis, may lead to HBsAg clearance in some patients, especially among Caucasians, but the risk of recurrence after discontinuation cannot be neglected. The treatment strategies based on pegylated interferon-α exhibit a higher potential for active HBsAg clearance, and some novel immunomodulators have also shown preliminary efficacy. Overall, for patients with HBsAg <100 IU/mL previously treated with NAs, treatment discontinuation or active combination treatment should be carefully assessed based on individual risk-benefit profiles. In the future, it is essential to incorporate more refined biomarkers for precise stratification and explore novel combination regimens with finite treatment courses that are safe and highly effective, in order to help more patients achieve clinical cure and reduce long-term risks of liver disease.
2.Application prospects of mitochondrial pyruvate carrier inhibitors in treatment of metabolic dysfunction-associated steatohepatitis
Journal of Clinical Hepatology 2026;42(4):938-942
Metabolic dysfunction-associated steatohepatitis (MASH) is a complex liver disease characterized by abnormal fat accumulation in the liver, accompanied by inflammation and hepatocyte injury, and it can gradually progress to liver fibrosis, liver cirrhosis, and even hepatocellular carcinoma. MASH has a complex pathogenesis involving multiple links such as insulin resistance, de novo lipogenesis (DNL), oxidative stress, and mitochondrial dysfunction. In recent years, mitochondrial pyruvate carrier (MPC) has attracted wide attention as a key molecular target for regulating lipid metabolism. This article systematically reviews the mechanism of action of MPC in MASH, with a focus on how inhibiting MPC expression regulates lipid synthesis and metabolism by reducing DNL production and modulating signaling pathways such as AMPK-ACC, thereby improving liver inflammation. In addition, this article discusses the potential application prospects of MPC inhibitors in MASH treatment, in order to provide new ideas for future clinical research on MASH management.
3.Consistent Detection of Aquaporin-4 Antibodies:A Comparative Analysis Between Fixed and Live Cell-Based Assays
Jing WANG ; Linge WANG ; Xiaolin YANG ; Zhizhong LI ; Jinyu JIANG ; Qiao XU ; Siyuan HUANG ; Qing FU ; Yang YANG ; Rongrong ZHANG ; Lin YANG ; Ai CHEN ; Xiaopeng ZENG ; Ke XU ; Peng ZHENG ; Xinyue QIN ; Jinzhou FENG
Journal of Clinical Neurology 2026;22(2):212-220
Background:
and Purpose Live cell-based assays (LCBA) are increasingly used for serological antibody detection due to their ability to preserve antigen conformation, offering moderately higher sensitivity than fixed cell-based assays. However, the clinical necessity of prioritizing LCBA for the detection of aquaporin-4 immunoglobulin G (AQP4-IgG) in neuromyelitis optica spectrum disorder (NMOSD) remains unclear, especially when compared to its established role in diagnosing myelin oligodendrocyte glycoprotein antibody-associated disease.
Methods:
We compared the performance of live cell-based assays using immunofluorescence (LCBA-IF) and fixed cell-based assays using immunofluorescence (FCBA-IF) in detecting AQP4-IgG in 90 cases of NMOSD meeting 2015 International Panel for Neuromyelitis Optica Diagnosis criteria, alongside 40 controls. Additionally, we further investigated the relationship between AQP4-IgG titers as measured by LCBA-IF and FCBA-IF and clinical parameters in NMOSD patients.
Results:
Results showed 96.9% agreement between LCBA-IF and FCBA-IF (Cohen’s κ=0.935), with a strong Spearman correlation (0.977, p<0.001). Both methods demonstrated 100% specificity, with LCBA-IF showing slightly higher sensitivity compared to FCBA-IF. Within LCBAIF-tested groups, statistically significant differences in annualized relapse rates were observed across all pairwise comparisons (low-titer vs. moderate-titer, low-titer vs. high-titer, and moderate-titer vs. high-titer; all p<0.050). However, this association reached statistical significance in some FCBA-IF-tested groups.
Conclusions
Overall, there is a strong concordance between LCBA-IF and FCBA-IF in detecting AQP4-IgG, where LCBA-IF shows slightly higher sensitivity. Furthermore, there is a potential link between elevated AQP4-IgG titers and an increased risk of relapse, and this correlation may appear more pronounced when using LCBA-IF.
4.Research advances in yttrium-90 microsphere selective internal radiation therapy in treatment of hepatocellular carcinoma
Yongle ZHAO ; Honglin CHEN ; Han ZHANG ; Xinyue ZHU ; Zhicheng YANG ; Maoting TAN ; Hongyun ZHAO
Journal of Chongqing Medical University 2025;50(8):1035-1041
Primary liver cancer is one of the most common causes of cancer-related deaths in China,with hepatocellular carcinoma(HCC)accounting for 75%-85%.Approximately 70%of HCC patients are in the advanced stage at the time of diagnosis and miss the opportunity for radical surgery,leading to a poor prognosis.Yttrium-90 microsphere selective internal radiation therapy(90Y-SIRT),an emerging therapeutic modality,delivers radioactive microspheres via the hepatic artery to target tumors and uses beta radiation for localized tumor ablation.Compared to conventional transarterial chemoembolization and pharmacotherapy,90Y-SIRT shows the advan-tages of significant clinical benefits,good safety profiles,and broad applicability across diverse patient populations.This article re-views the advances in the application of 90Y-SIRT in HCC treatment.
5.Auditory and speech features in vestibular schwannoma patients with sudden sensorineural hearing loss as the first symptom
Ying SHI ; Xinyue ZOU ; Biao CHEN ; Xiaohan DU ; Xinping HAO
Chinese Archives of Otolaryngology-Head and Neck Surgery 2025;32(9):557-560
OBJECTIVE To investigate the differences in audiological characteristics and speech recognition rates between vestibular schwannoma(VS)patients presenting with sudden sensorineural hearing loss(SSNHL)as first symptom and patients with idiopathic sudden deafness(ISD),in order to provide a reference for clinical diagnosis and differential diagnosis.METHODS A retrospective analysis was conducted on 60 patients with VS presenting as SSNHL(VS group),and 60 patients with unilateral ISD(SD group).Pure-tone thresholds,audiogram configurations,and speech recognition scores were compared between the two groups.Statistical analyses were performed using t-test,Mann-Whitney U test,and chi-square test.RESULTS Hearing loss in the VS group was mainly distributed in the moderate to profound range,and the proportion of descending-type audiograms was significantly higher than that in the SD group(χ2=13.97,P=0.002 9).In contrast,the SD group was predominantly characterized by mild to moderate hearing loss and flat-type audiograms.Regarding speech recognition,the VS group showed significantly poorer monosyllabic recognition(38.6%±40.4%)and sentence recognition(53.4%±42.0%)compared with the SD group(59.0%±37.8%,75.8%±36.0%,P<0.01).Notably,some VS patients exhibited complete loss of speech recognition even before the pure-tone average reached the level of total deafness.CONCLUSION VS patients presenting with SSNHL showed significant differences in audiogram configurations and speech recognition compared with those with ISD.A marked decline in speech recognition,combined with a typical descending-type audiogram,may serve as important clinical indicators,suggesting that early imaging examinations should be performed to confirm the diagnosis.
6.The Overview and Future Trend of High-quality Clinical Randomized Controlled Trial of Acupuncture for Neurological Disorders
Jin YAO ; Qiongnan BAO ; Kexin WU ; Wanqi ZHONG ; Xinyue ZHANG ; Ziwen CHEN ; Zihan YIN ; Fanrong LIANG
World Science and Technology-Modernization of Traditional Chinese Medicine 2025;27(4):973-981
Objective Neurological disorders,constitute the majority of acupuncture-treated ailments.By critically examining a comprehensive selection of high-quality clinical randomized controlled trials(RCTs)from both domestic and international sources,we aimed to uncover the prevailing hot research topic and potential future directions in acupuncture therapy for these conditions.Methods Four databases,including PubMed,Web of science,Cochrane Library and EMBASE were searched.The search period is set from the establishment of each database to November 30,2023.And the search content was RCTs of acupuncture for neurological diseases classified as Ⅰ and Ⅱ by the Chinese Academy of Sciences were extracted.Key aspects extracted included annual publication volume,journals,disease types,outcomes,conclusions,acupuncture methods and control groups.Results A total of 81 high-quality RCTs were identified,revealing a consistent annual publication trend of acupuncture for neurological disorders.Key journals contributing to this research were Cephalalgia,Clinical Rehabilitation and Clinical Journal Of Pain,etc.The studies predominantly focused on migraine and sequela of apoplexy with migraine days/frequency and Ashworth scale and its modifications as commonly used primary outcome indicators,respectively.Overall,there were 73 RCTs that concluded that acupuncture for neurologic disorders were effective,8 were ineffective.The acupuncture methods were diverse,encompassing acupuncture,individualized acupuncture and transcutaneous electrical nerve stimulation,etc.The control measures were also varied,featuring sham acupuncture,sham-acupoint and micro-needle,etc.Conclusion With the development of acupuncture RCTs,their international influence has expanded.Research has shifted from validation of effectiveness to exploration of mechanisms,and despite the expansion of the disease spectrum of acupuncture,acupuncture trials have yet to be regulated and standardized,and the assessment of acupuncture efficacy remains controversial and challenging for the discipline.It is recommended to promote multi-center cooperation and strengthen the training of trialists etc.to provide more high-quality clinical evidence.
7.Progress in research on the application of gamma-aminobutyric acid in the treatment of ophthalmic diseases
Ruofan XI ; Zhanglong LI ; Xinyue CHEN ; Yuecong SUN ; Hongsheng BI ; Ping ZHAO
Recent Advances in Ophthalmology 2025;45(8):659-662,672
γ-Aminobutyric acid(GABA),a pivotal inhibitory neurotransmitter in the central nervous system,plays an essential role in maintaining normal ocular physiological functions.GABA and its receptors are widely distributed through-out the retina,optic nerve,and visual pathways.Research indicates that GABA dysregulation is implicated in the pathogen-esis and progression of certain ophthalmic disorders.This article provides a comprehensive exploration of the relationship between GABA and ophthalmic diseases,including myopia,amblyopia,glaucoma,and dry eye syndrome.Moreover,the potential mechanisms and recent research advances are discussed.The findings may offer novel options and chances for the diagnosis and treatment of ophthalmic diseases.
8.The status and influencing factors of acceptance of disability in young and middle-aged spinal cord injury patients
Rui ZHAO ; Songmei WU ; Junxian CHEN ; Xinyue LIANG ; Yujiao LU ; Erhuan HAN
Chinese Journal of Nursing 2025;60(18):2231-2238
Objective To investigate the current status of acceptance of disability(AOD)among young and middle-aged spinal cord injury patients and analyze the factors influencing it,in order to provide a basis for nursing managers to develop targeted interventions.Methods From February to July 2024,a convenience sample of 330 young and middle-aged spinal cord injury patients who were hospitalized in 3 tertiary-level hospitals in Henan Province was selected.The survey was conducted using a general information questionnaire,the Brief Adaptation to Disability Scale-Revised,Perceived Social Support Scale,Connor-Davidson Resilience Scale-10 item,Brief Illness Perception Questionnaire,Medical Coping Modes Questionnaire.Results A total of 322 patients were included in the final analysis,yielding a valid response rate of 97.58%.The AOD score for young and middle-aged spinal cord injury patients was(25.99±6.68).Multiple linear regression analysis revealed that gender,education level,type of paralysis,injury duration,pain intensity,social support,psychological resilience,disease perception,and coping styles(confrontation and submission)were influencing factors of AOD(P<0.05).Conclusion AOD among young and middle-aged spinal cord injury patients is at a moderate level.Healthcare professionals should pay particular attention to male patients,those with low literacy,quadriplegia,shorter injury durations,high pain intensity,low social support,weak psychological resilience,strong disease perception,and yielding coping styles.Timely interventions are recommended to enhance AOD,strengthen rehabilitation outcomes,and improve prognosis.
9.Research progress on drug preparations of rectal administration for ulcerative colitis
Jun WAN ; Lisha ZHOU ; Tiantian LUO ; Xinyue ZHANG ; Shiyao CHEN ; Xia ZHOU
China Pharmacy 2025;36(7):887-890
Ulcerative colitis (UC), which is characterized by a complex and multifactorial etiology, remains one of the challenging disorders in the international field of digestive system diseases. In recent years, rectal administration preparations have made rapid progress in UC therapeutic applications. This study systematically reviews the dosage forms, mechanisms of action, and clinical applications of rectally-administered preparations for the treatment of UC. It is found that suppositories are the most commonly used dosage forms for rectal administration. The newer suppositories have the advantages of high bioavailability and good stability. Enemas can retain the drug in the intestine as much as possible to achieve the effects of diluting intestinal toxins, cleansing the bowel, and reducing inflammation. Gels can achieve a drug-sustained-release effect and effectively improve intestinal mucosal damage. The mechanism of action of this type of preparation is mainly to inhibit inflammatory cell infiltration, regulate intestinal microbial homeostasis, and increase the expression of tight-junction proteins, so as to play anti-inflammatory, regulate the intestinal bacterial flora, repair the intestinal mucosa, and other efficacies. The diversity of rectal administration forms provides a wide range of choices for the clinical treatment of UC, such as Mesalazine suppositories, Lianshao enemas, and temperature- sensitive gels loaded with drugs for UC.
10.Survival impact of corticosteroid and immunosuppressant management strategies for immune-related adverse events in immune checkpoint inhibitor-treated patients:a systematic review and meta-analysis
Xinyue LAN ; Yicheng ZHOU ; Dongqin CHEN
China Oncology 2025;35(10):906-919
Immune checkpoint inhibitors(ICIs)have revolutionized cancer therapy,but their use is frequently complicated by immune-related adverse events(irAEs),which often require management with corticosteroids or additional immunosuppressive agents.The prognostic impact of these therapeutic strategies in the setting of irAEs has not been systematically elucidated.This systematic review and meta-analysis aimed to evaluate the impact of corticosteroid(CS)and second-line immunosuppressant(IM)use on survival outcomes among patients who developed irAEs during ICI therapy.Following a preregistered protocol(PROSPERO CRD1144835),we systematically searched PubMed,Embase,Web of Science,Cochrane Library,SinoMed,CNKI and Wanfang to identify studies published in the past 10 years(up to May 2025)reporting on the association between CS and IM use and survival outcomes in ICI-treated patients with irAEs.Two reviewers independently performed study selection,data extraction,and quality assessment.Meta-analyses were performed using R software.A total of 11 studies comprising 7 255 patients were included.Meta-analysis showed that CS use versus no use was not significantly associated with overall survival(OS)(HR=0.73,95%CI:0.45-1.18)or progression-free survival(PFS)(HR=0.68,95%CI:0.00-98.01).For post-irAE survival outcomes,higher cumulative CS dose(per 1 000 mg increment)was associated with a mild protective effect on post-irAE OS(HR=0.95,95%CI:0.92-0.98)and post-irAE PFS(HR=0.96,95%CI:0.94-0.99).In contrast to CS alone,IM use in combination with CS was associated with significantly increased risk of disease progression or death for post-irAE OS(HR=1.40,95%CI:1.11-1.76)and post-irAE PFS(HR=1.32,95%CI:1.08-1.62).Sensitivity analyses demonstrated good robustness of the main significant results.Current evidence suggests that CS and IM management strategies may differentially affect survival outcomes in patients with irAEs following ICI therapy.Increased cumulative CS dose is not associated with worse outcomes,whereas the addition of second-line IMs may increase the risk of adverse survival outcomes.Further prospective studies are warranted to optimize irAE management strategies and to balance the risks of immunosuppressive therapy with anticancer efficacy.

Result Analysis
Print
Save
E-mail